BIT225 and Ebola

It's recently been reported that the nurse cured of Ebola had a relapse some months after she was discharged as cured. Apparently, the Ebola virus can lurk unassailable by conventional drugs, in hiding spots such as the eyes or central nervous sytem and emerge later to re-endanger the poor victim. This is also the case with HIV and some other vituses.

One wonders if this is a significant pointer to the possible value of BIT225 and other viroporins. Surely the company is onto this?

As I've said repeatedly, the intellectual property surrounding this drug as represented by Biotron's patent portfolio is worth a lot more than just its HCV potential.